Skip to content

Medical emergency? What to do

Gene Expression May Influence Lack of Response to RA Treatment

3-RXPublished October 26, 20086 min read

Key points

  • Genes might explain why some patients with rheumatoid arthritis respond better to anti-TNF therapy than others, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco, Calif.
  • Drugs known as tumor necrosis factor, or TNF, inhibitors are often prescribed to individuals with rheumatoid arthritis.
  • While all cells in an individual contain the same genetic material, different cells may produce, or express, differing amounts of individual genes.
  • This gene expression analysis was also studied in 30 U.S. patients with RA, confirming that lack of response to anti-TNF treatment is associated with a low expression of these two exons.

Genes might explain why some patients with rheumatoid arthritis respond better to anti-TNF therapy than others, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco, Calif.

Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints are the principal body parts affected by RA, inflammation can develop in other organs as well. An estimated 1.3 million Americans have RA, and the disease typically affects women twice as often as men.

Drugs known as tumor necrosis factor, or TNF, inhibitors are often prescribed to individuals with rheumatoid arthritis. They work by targeting and blocking the inflammation, and can help reduce pain, morning stiffness, tender and swollen joints, limit damage to the joints and improve function.

Treatment strategies used in blocking tumor necrosis factor have been very successful in treating patients with RA. For reasons that are unknown, significant numbers of these patients do not respond to this type of treatment, and there are currently no means by which to identify these patients in advance of treatment.

While all cells in an individual contain the same genetic material, different cells may produce, or express, differing amounts of individual genes.

Researchers analyzed the gene expression in the white blood cells of 42 Dutch patients with RA prior to starting TNF inhibitor therapy. They identified patterns in gene expression levels in a group of 34 genes that were associated with responsiveness to anti-TNF therapy. These genes included the inflammatory genes PTGS2, EGR1, IL8 and IL28A. Researchers also identified a gene that showed a decrease in expression of two particular gene components, called exons, in patients who did not respond to anti-TNF medications, in comparison to those who did.

This gene expression analysis was also studied in 30 U.S. patients with RA, confirming that lack of response to anti-TNF treatment is associated with a low expression of these two exons. This suggests that the particular gene expression patterns in RA patients may serve as new biomarkers for predicting response to therapy with anti-TNF drugs.

“Patients with rheumatoid arthritis are often treated with medication directed to tumor necorsis factor alpha, anti-TNF therapy,” explains Marieke Coenen, PhD; Nijmegen Centre for Molecular Life Sciences and Institute of Genetic and Metabolic Disease, research lab for multifactorial diseases, division of DNA-diagnostics, department of human genetics, Radboud University Nijmegen Medical Centre, Nijmengen, The Netherlands, and lead investigator in the study. “Given the extremely high costs of anti-TNF therapy and the risk of adverse effects, it would be beneficial to predict whether an individual patient will benefit from this treatment, beforehand. In this study we identified a gene that might be used to determine which patients will respond to anti-TNF treatment.”

Patients should talk to their rheumatologists to determine their best course of treatment.

The ACR is an organization of and for physicians, health professionals, and scientists that advances rheumatology through programs of education, research, advocacy and practice support that foster excellence in the care of people with or at risk for arthritis and rheumatic and musculoskeletal diseases. For more information on the ACR’s annual meeting, see www.rheumatology.org/annual.

Editor’s Notes: Dr. Coenen will present this research during the ACR Annual Scientific Meeting at the Moscone Center from 3:00 – 3:15 PM on Monday, October 27, in Room 102. Dr. Coenen will be available for media questions and briefing at 8:30 AM on Monday, October 27 in the on-site press conference room, 114.

Presentation Number: 1204

Gene Expression Profiling of Rheumatoid Arthritis Patients Treated with Anti-Tumour Necrosis Factor

Marieke J.H. Coenen1, Erik J.M. Toonen1, Franak Batliwalla2, Piet L.C.M. van Riel1, Wietske Kievit1, Joris A. Veltman1, Agnes M.M. Eijsbouts3, Christian F.H.A. Gilissen1, Aarti Damle2, Hans Scheffer1, Timothy R.D.J. Radstake1, Peter K. Gregersen2, Pilar Barrera1, Barbara Franke1. 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 2The Feinstein Institute for Medical Research, Manhasset, NY; 3Sint Maartenskliniek, Nijmegen, Netherlands

Purpose: Treatment strategies blocking TNFα have proven very successful showing beneficial effects in at least 60% of the patients with rheumatoid arthritis(RA). However, a significant subset of patients do not respond for reasons that are unknown 1,2, and there is currently no means of identifying these patients. In this study we test the hypothesis that gene expression profiles can be used to predict anti-TNF response and we examine the effect of therapy on these profiles.

Methods: Expression profiles of white blood cells of 42 patients before therapy were analyzed using the Affymetrix GeneChip® Human Exon 1.0 ST Array. The search was focused on the differences in gene expression between treatment responders and non-responders at baseline. Treatment responses were assessed using European League Against Rheumatism (EULAR) response criteria.
Results: We identified expression profiles of a subset of 34 genes that are able to distinguish between anti-TNF responders and non-responders. Genes in this subset included the inflammatory genes PTGS2, EGR1, IL8 and IL28A. We also identified a gene which showed a decrease in expression of two exons in anti-TNF non-responders compared to responders. The results were verified using quantitative PCR. Analysing the expression of the two exons in 32 patients of our cohort (DREAM) and in 30 patients from a U.S. cohort (ABCoN) showed that non-response was significantly associated with a low expression of the two exons.

Conclusions: The identified gene expression patterns and splice variants may serve as new biomarkers for predicting anti-TNF response.
1. Coenen, M. J., Toonen, E. J., Scheffer, H., Radstake, T. R., Barrera, P., and Franke, B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics, 8: 761-773, 2007.
2. Toonen, E. J., Barrera, P., Radstake, T. R., van Riel, P. L., Scheffer, H., Franke, B., and Coenen, M. J. Gene Expression Profiling in Rheumatoid Arthritis; current concepts and future direction. Ann Rheum Dis, Epub February 2008.

Disclosure Block: M.J. Coenen, None; E.J. Toonen, None; F. Batliwalla, None; P.L. van Riel, None; W. Kievit, None; J.A. Veltman, None; A.M. Eijsbouts, None; C.F. Gilissen, None; A. Damle, None; H. Scheffer, None; T.R. Radstake, None; P.K. Gregersen, consultant for Roche, 9; P. Barrera, None; B. Franke, None.

Source: American College of Rheumatology (ACR)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.